SAN CLEMENTE, Calif., Oct 18, 2006 (BUSINESS WIRE) -- Metagenics, Inc., a privately held company focused on developing and manufacturing science-based nutraceuticals and medical foods, announced that Nobel laureate Louis J. Ignarro, PhD has joined the company's scientific advisory board.
Dr. Ignarro is one of the recipients of the 1998 Nobel Prize in Physiology or Medicine for demonstrating the cardiovascular signaling properties of nitric oxide. He is a distinguished professor of pharmacology at the University of California at Los Angeles, and a former professor of pharmacology at Tulane University. His research has been recognized by pharmaceutical companies Lily and Merck, and he received the Basic Research Prize of the American Heart Association in 1998 in recognition of his outstanding contributions to the advancement of cardiovascular science. He has also been inducted into the National Academy of Sciences and the American Academy of Arts and Sciences.
He is the founder of the Nitric Oxide Society, and founder and editor-in-chief of Nitric Oxide Biology and Chemistry. Dr. Ignarro is the author and co-author of several books and numerous articles in peer-reviewed journals. He recently co-authored with Metagenics' own Dr. Jeffrey S. Bland an editorial commentary on a recent review of arginine and vascular health that appears in the latest Journal of the American Nutraceutical Association.
"We are very excited to have Dr. Louis Ignarro join us in an advisory position," said Jeffrey S. Bland, PhD, Chief Science Officer and President of MetaProteomics(R), who is respected in the field of functional medicine and also serves on the advisory board. "The caliber of researchers and scientific professionals on this board is an indicator of the inspiring potential for Metagenics in developing further advancements in nutritional approaches to health."
The Metagenics scientific advisory board provides guidance for the future of Metagenics and the MetaProteomics Nutrigenomics Research Center. This board is comprised of a highly credentialed group that represents a wealth of international experience from scientific research, business, and clinical practice. In addition to Dr. Ignarro and Dr. Bland, board members include:
-- Edward A. Dennis, PhD, director of the LIPID MAPS consortium grants from the National Institutes of Health (NIH) who is also a chemistry and biochemistry professor at the University of California at San Diego and adjunct professor at Scripps Research Institute.
-- Joel M. Evans, MD, obstetrician/gynecologist and director of The Center for Women's Health in Stamford, Conn. who has also been recognized for his service and guidance in congressional healthcare reform.
-- Barry M. Forman, MD, PhD, director of the gene regulation and drug discovery department and professor at the Beckman Research Institute who has also been recognized by the Nobel Assembly and American Society for Biochemistry and Molecular Biology for his research in furthering the understanding of disease.
-- David A. Jenkins, MD, PhD, DSc, who is credited with developing the concept of glycemic index and is a professor and research chair at the University of Toronto and director of the Clinical Nutrition and Risk Factor Modification Center at St. Michael's Hospital.
-- John F.W. Keana, PhD, professor emeritus of synthetic organic and medicinal chemistry at the University of Oregon who received the NIH Research Career Development Award for his work that focuses on the problem-solving applications of novel molecules.
-- Philipp E. Scherer, PhD, associate professor of cell biology and medicine in the Albert Einstein College of Medicine who received the 2005 Outstanding Scientific Achievement Award of the American Diabetes Association for his influential diabetes research.
-- Robert H. Lerman, MD, PhD, former hospital chief of medicine and current Medical Director of Metagenics, Inc. and the Functional Medicine Research Center.
-- Matthew L. Tripp, PhD, microbiologist and physiologist who led research in Fortune 500 companies and currently serves as Vice President of Research & Development for Metagenics, Inc. and MetaProteomics.
"Research continues to show that natural substances can have a positive effect in managing or preventing chronic illnesses," said Jeff Katke, Chairman and CEO of Metagenics, Inc. "Our goal is to build on that research in our technologically advanced facilities and develop practical applications to improve patient health. We are fortunate to have the support and advice of such industry-leading professionals to help us in our mission."
About Metagenics, Inc.
Metagenics, Inc. is a leading developer and manufacturer of science-based nutraceuticals sold to healthcare practitioners worldwide as approaches to leading health concerns. The company is headquartered in San Clemente, Calif., with manufacturing and multiple research facilities located in Gig Harbor, Wash. -- including its Functional Medicine Research Center(SM) for human clinical research. Metagenics holds multiple proprietary formula patents and produces over 400 research-based products to optimize health. The company demonstrates its commitment to purity and quality through its certifications for Good Manufacturing Practices (GMP) from the NNFA, NSF International, and TGA. For more information about Metagenics, please visit the company's Web site at www.metagenics.com.
About the MetaProteomics Nutrigenomics Research Center
The MetaProteomics(R) Nutrigenomics Research Center -- located in the Metagenics functional medicine campus in Gig Harbor, Wash. -- was established to test active substances from food and other natural sources that can serve as potent dietary signaling molecules to positively affect genetic expression (the science of nutrigenomics). Similar to the development of pharmaceutical applications, MetaProteomics employs cell line testing on isolated bioactive molecules extracted from natural sources to identify their ability to modify cellular function related to various disease processes. When a successful combination is identified, it undergoes other laboratory tests and then is formulated for human clinical research. Metagenics is the only known manufacturer of professional formulas that utilizes this revolutionary methodology to set new standards in the safety and effectiveness of natural approaches.